Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965997 | 0.86 | LMNA (0.38) | LMNAADRA1A | |
| Hydrochloric Acid SCHEMBL6968897 | 0.85 | SIGMAR1 (0.38) | LMNAADRA1A | |
| SCHEMBL6967355 | 0.85 | ADRA1A (0.49) | LMNAADRA1A | |
| SCHEMBL6967165 | 0.84 | KDM1A (0.39) | ADRA1ATDP1 | |
| SCHEMBL6963118 | 0.83 | LTA4H (0.46) | LTA4HADRA1A | |
| SCHEMBL6957018 | 0.81 | SLC6A2 (0.53) | ADRA1ATDP1 | |
| SCHEMBL6954587 | 0.81 | ADRA1A (0.48) | ADRA1A | |
| SCHEMBL6956969 | 0.80 | CYP2D6 (0.43) | — | |
| SCHEMBL6962031 | 0.78 | SLC6A2 (0.42) | ADRA1A | |
| SCHEMBL6960181 | 0.78 | MAOB (0.43) | LMNAADRA1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | LMNA 3659/4885LTA4H 375/4885ADRA1A 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.